Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Simes

Showing results (11-20 of 264) with videos related to

Pageof 27
Sort By:
Annals of Internal Medicine|June 7, 2006
When is measuring sensitivity and specificity sufficient to evaluate a diagnostic test, and when do we need randomized trials?Sarah J Lord, Les Irwig, R John Simes
The Medical Journal of Australia|September 12, 2022
Changes to design and analysis elements of research plans during randomised controlled trials in AustraliaXanthi Coskinas, R John Simes, Andrew J Martin
The Medical Journal of Australia|August 7, 2012
The role of statin therapy in patients with lower vascular riskAnthony C Keech, Jordan R Fulcher, John Simes
The New England Journal of Medicine|February 22, 2013
Aspirin for preventing venous thromboembolismTimothy A Brighton, John W Eikelboom, John Simes
The Medical Journal of Australia|July 25, 2013
A funding model for public-good clinical trialsIngrid M Winship, John McNeil, R John Simes
The Medical Journal of Australia|April 30, 2004
Subgroup analysis: application to individual patient decisionsR John Simes, Val J Gebski, Anthony C Keech
Contemporary Clinical Trials|August 28, 2021
Reacting to prognostic covariate imbalance in randomised controlled trialsXanthi Coskinas, I Manjula Schou, John Simes, et al.
Trials|June 5, 2020
Changes to aspects of ongoing randomised controlled trials with fixed designsXanthi Coskinas, John Simes, Manjula Schou, et al.
American Heart Journal|April 8, 2003
Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) studyWendy Hague, Peta Forder, John Simes, et al.
European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology|September 10, 2009
Laboratory and non-laboratory-based risk prediction models for secondary prevention of cardiovascular disease: the LIPID studyJisheng Cui, Andrew Forbes, Adrienne Kirby, et al.
Pageof 27

Showing results (11-20 of 264) with videos related to

Sort By:
Pageof 27
Annals of Internal Medicine|June 7, 2006
When is measuring sensitivity and specificity sufficient to evaluate a diagnostic test, and when do we need randomized trials?Sarah J Lord, Les Irwig, R John Simes
The Medical Journal of Australia|September 12, 2022
Changes to design and analysis elements of research plans during randomised controlled trials in AustraliaXanthi Coskinas, R John Simes, Andrew J Martin
The Medical Journal of Australia|August 7, 2012
The role of statin therapy in patients with lower vascular riskAnthony C Keech, Jordan R Fulcher, John Simes
The New England Journal of Medicine|February 22, 2013
Aspirin for preventing venous thromboembolismTimothy A Brighton, John W Eikelboom, John Simes
The Medical Journal of Australia|July 25, 2013
A funding model for public-good clinical trialsIngrid M Winship, John McNeil, R John Simes
The Medical Journal of Australia|April 30, 2004
Subgroup analysis: application to individual patient decisionsR John Simes, Val J Gebski, Anthony C Keech
Contemporary Clinical Trials|August 28, 2021
Reacting to prognostic covariate imbalance in randomised controlled trialsXanthi Coskinas, I Manjula Schou, John Simes, et al.
Trials|June 5, 2020
Changes to aspects of ongoing randomised controlled trials with fixed designsXanthi Coskinas, John Simes, Manjula Schou, et al.
American Heart Journal|April 8, 2003
Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) studyWendy Hague, Peta Forder, John Simes, et al.
European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology|September 10, 2009
Laboratory and non-laboratory-based risk prediction models for secondary prevention of cardiovascular disease: the LIPID studyJisheng Cui, Andrew Forbes, Adrienne Kirby, et al.
Pageof 27